LEHI, Utah , Aug. 6, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company, today announced that Dr. David J.
Bearss , President and CEO, and a renowned drug developer, will be giving an oral presentation highlighting the company's latest research on the impact of chronic inflammation on human health span and aging at the 3rd Edition Global Longevity Federation , held on August 12-13, 2024 , in Rome, Italy . Presentation Title: The Impact of Chronic Inflammation on Human Health Span and Aging Date and Time: August 12, 2024, from 5:15 p.m.
to 5:45 p.m. CET Abstract: Chronic inflammation has emerged as a pivotal factor influencing health span and aging, playing a crucial role in the onset and progression of age-related diseases.
Dr. Bearss' research delves into the complex relationship between chronic inflammation and human health span, highlighting its significant impact on aging processes. Chronic inflammation, marked by persistent immune system activation, affects cellular and molecular pathways related to aging.
By dysregulating inflammatory mediators such as cytokines, chemokines, and reactive oxygen species, chronic inflammation accelerates cellular senescence, disrupts tissue homeostasis, and promotes age-related diseases like cardiovascular disease, neurodegeneration, and cancer. Furthermore, chronic inflammation disrupts the balance between pro-inflammatory and anti-inflammatory mechanisms, leading to sustained tissue damage and impaired r.